Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

Summary

This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.

Timeline

Start

2020-03-20

Primary completion

2023-12-20

Completion

2023-12-20

Drugs

Indications